| irAE | immune related adverse event |
| ICI | immune checkpoint inhibitor |
| mOS | median overall survival |
| PD-1 | programmed death 1 |
| PD-L1 | programmed death-ligand 1 |
| CTLA-4 | cytotoxic T-lymphocyte –associated protein 4 |
| CNS | central nervous system |
| RECIST | Response Evaluation Criteria In Solid Tumors |
| CTCAE | Common Terminology Criteria for Adverse Events |
| TPS | tumor proportion score |
| NCCN | National Comprehensive Cancer Network |